See today's BioWorld MedTech
To read the full story, subscribe or sign in.

ACLA urges FDA to withdraw draft rule for lab-developed tests

Dec. 5, 2023
By Mark McCarty
The U.S. FDA’s draft rule for regulation of lab-developed tests (LDTs) was accorded a mere 60 days for comment, but nonetheless drew support from a number of stakeholders, including Foundation Medicine of Cambridge, Mass.
BioWorld MedTech Regulatory Diagnostics U.S. FDA